Figure 1.
Figure 1. Met-α2AP and Asn-α2AP cross-linking to fibrin and their plasmin-inhibitory activity. (A) Time-dependent cross-linking of Met-α2AP and Asn-α2AP to fibrin by FXIIIa catalysis. Solutions of purified human α2AP, fibrinogen, and FXIII were clotted with thrombin and CaCl2, and at the indicated times above each gel lane, clotting was terminated by solubilizing in urea-SDS-DTT. Non–cross-linked α2AP and α2AP-fibrin cross-linked complexes were detected by immunoblot analysis. (B) Densitometric analysis of the percent incorporation of α2AP into fibrin. Each data point is the mean ± SD of 3 experiments. (C) Plasmin-inhibitory activity of Met-α2AP and Asn-α2AP. In control sample, α2AP was replaced with reaction buffer. Each α2AP was incubated with an equimolar amount of plasmin for selected incubation periods, and then using a plasmin chromogenic substrate (S-2251) residual plasmin activity was assayed by a published method.10 Each data point is the average of 2 experiments.

Met-α2AP and Asn-α2AP cross-linking to fibrin and their plasmin-inhibitory activity. (A) Time-dependent cross-linking of Met-α2AP and Asn-α2AP to fibrin by FXIIIa catalysis. Solutions of purified human α2AP, fibrinogen, and FXIII were clotted with thrombin and CaCl2, and at the indicated times above each gel lane, clotting was terminated by solubilizing in urea-SDS-DTT. Non–cross-linked α2AP and α2AP-fibrin cross-linked complexes were detected by immunoblot analysis. (B) Densitometric analysis of the percent incorporation of α2AP into fibrin. Each data point is the mean ± SD of 3 experiments. (C) Plasmin-inhibitory activity of Met-α2AP and Asn-α2AP. In control sample, α2AP was replaced with reaction buffer. Each α2AP was incubated with an equimolar amount of plasmin for selected incubation periods, and then using a plasmin chromogenic substrate (S-2251) residual plasmin activity was assayed by a published method.10 Each data point is the average of 2 experiments.

Close Modal

or Create an Account

Close Modal
Close Modal